PDGFR Signaling blockade in marrow stroma impairs lung cancer bone metastasis

Cancer Research

Volumn 71, Issue 1, 2011, Pages 164-174

  Catena, Raúl ^a,b   Luis Ravelo, Diego ^a   Antón, Iker ^a   Zandueta, Carolina ^a   Salazar Colocho, Pablo ^a   Larzábal, Leyre ^a   Calvo, Alfonso ^a   Lecanda, Fernando ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTEGRIN; ALPHA3 INTEGRIN; ALPHA4 INTEGRIN; ALPHA6 INTEGRIN; BETA CATENIN; BETA1 INTEGRIN; BETA2 INTEGRIN; BETA5 INTEGRIN; COLLAGEN TYPE 2; COLLAGEN TYPE 4; COLLAGEN TYPE 5; COLLAGEN TYPE 6; COLLAGEN TYPE 7; COLLAGEN TYPE 8; COLONY STIMULATING FACTOR 1; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LAMININ; MATRIX METALLOPROTEINASE 14; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SCLEROPROTEIN; STROMELYSIN 3; SUNITINIB; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNINDEXED DRUG; UVOMORULIN; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE; BONE MARROW; BONE METASTASIS; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CELL HOMING; CELL MIGRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; BONE NEOPLASMS; CELL ADHESION; CELL LINE; CELL PROLIFERATION; GENE EXPRESSION PROFILING; HUMANS; INDOLES; LUNG NEOPLASMS; MICE; NEOPLASM INVASIVENESS; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 78651405675     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1708     Document Type: Article

References (37)

1. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
2. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
3. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94.
4. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-52.
5. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-3.
6. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
7. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
8. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002;277:24571-8.
9. Yin JJ, Pollock CB, Kelly K, Kakonen SM, Selander KS, Chirgwin JM, et al. Mechanisms of cancer metastasis to the bone. Cell Res 2005;15:57-62.
10. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206.
11. Vicent S, Luis-Ravelo D, Anton I, Garcia-Tunon I, Borras-Cuesta F, Dotor J, et al. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res 2008;68:2275-85.
12. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007;8:341-52.
13. Nakamura H, Hiraga T, Ninomiya T, Hosoya A, Fujisaki N, Yoneda T, et al. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice. J Bone Miner Metab 2008;26:642-7.
14. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
15. Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 2002;17:1921-5.
16. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
17. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-45.
18. Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. Expert Opin Investig Drugs 2009;18:821-34.
19. Heissig B, Werb Z, Rafii S, Hattori K. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb Haemost 2003;90:570-6.
20. Kopp HG, Hooper AT, Avecilla ST, Rafii S. Functional heterogeneity of the bone marrow vascular niche. Ann N Y Acad Sci 2009;1176:47-54.
21. Hooper AT, Butler JM, Nolan DJ, Kranz A, Iida K, Kobayashi M, et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell 2009;4:263-74.
22. Saharinen P, Alitalo K. Double target for tumor mass destruction. J Clin Invest 2003;111:1277-80.
23. Lai CF, Chaudhary L, Fausto A, Halstead LR, Ory DS, Avioli LV, et al. Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem 2001;276:14443-50.
24. Gonzalez I, Vicent S, de Alava E, Lecanda F. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. J Mol Med 2007;85:1015-29.
25. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
26. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A 1991;88:6642-6.
27. Ponomarev V, Doubrovin M, Serganova I, Vider J, Shavrin A, Beresten T, et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging 2004;31:740-51.
28. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010;70:1053-62.
29. Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004;23:2800-10.
30. Tejada ML, Yu L, Dong J, Jung K, Meng G, Peale FV, et al. Tumordriven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res 2006;12:2676-88.
31. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, , et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
32. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-66.
33. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006;6:307-12.
34. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
35. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
36. Kaplan RN, Riba RD, Zacharoulis S, Takeda T, Okuyama H, Vinals F, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
37. Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010;28:21-8.